Altimmune ( (ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead program being pemvidutide, a GLP-1/glucagon dual receptor agonist.
In its latest earnings report, Altimmune announced positive results from its IMPACT Phase 2b trial, highlighting the potential of pemvidutide as a differentiated therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company also provided updates on its financial performance and ongoing clinical trials.
Key highlights from the report include statistically significant MASH resolution and weight loss achieved by pemvidutide at 24 weeks, with improvements in liver inflammation and fibrosis markers. The company also reported a 39% increase in cash and short-term investments, totaling $183.1 million as of June 30, 2025. Altimmune’s research and development expenses decreased compared to the previous year, reflecting the timing of clinical trial costs.
Altimmune is preparing for an End-of-Phase 2 Meeting with the FDA, expected in the fourth quarter of 2025, to advance pemvidutide into Phase 3 development. The company is also conducting trials for pemvidutide in Alcohol Use Disorder and Alcohol-Associated Liver Disease, with promising preliminary data.
Looking ahead, Altimmune’s management remains optimistic about the potential of pemvidutide and is focused on advancing its clinical programs while maintaining a strong financial position to support future developments.